Vancin-S Special Precautions

Vancin-S 125 mg: This preparation is for oral use only and is not systemically absorbed. Orally administered Vancomycin capsules are not effective for other types of infections.
Absorption may be enhanced in patients with inflammatory disorders of the intestinal mucosa or C. difficile-induced pseudomembranous colitis. These patients may be at risk for the development of adverse reactions, especially if there is a concomitant renal impairment. Monitoring of serum Vancomycin concentrations of patients with inflammatory disorders of the intestinal mucosa should be performed.
Serial monitoring of renal function should be performed when treating patients with underlying renal dysfunction or patients receiving concomitant therapy with an aminoglycoside or other nephrotoxic drugs.
Serial tests of auditory function may be helpful in order to minimize the risk of ototoxicity in patients with an underlying hearing loss, or who are receiving concomitant therapy with an ototoxic agent such as an aminoglycoside.
Anti-motility agents should be avoided and proton pump inhibitor use should be reconsidered.
Severe cutaneous adverse reactions (SCARS) including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) and acute generalized exanthematous pustulosis (AGEP), which can be life-threatening or fatal, have been reported in association with Vancomycin treatment. Most of these reactions occurred within a few days and up to eight weeks after commencing treatment with Vancomycin.
At the time of prescription patients should be advised of the signs and symptoms and monitored closely for skin reactions. If signs and symptoms suggestive of these reactions appear, Vancomycin should be withdrawn immediately and an alternative treatment considered. If the patient has developed a SCAR with the use of Vancomycin, treatment with Vancomycin must not be restarted at any time.
Prolonged use of Vancomycin may result in the overgrowth of non-susceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.
Vancin-S: Necrosis or severe pain in intramuscular administration.
Impaired renal or auditory function.
Infant and elderly especially in combination w/ aminoglycosides.